• ADCs have attracted significant interest as highly targeted and potent medicines in many therapeutic areas.
• Development of ADCs have been complicated by the need to balance drug efficacy and safety, requiring extensive investigations into conjugation technologies and the resulting critical quality attributes of ADCs.
• Mycenax offers a simplified and reliable platform for the development of ADC manufacturing processes, enabling accelerated preclinical and clinical development.

Attached  ⇒ Understanding Process Development of Antibody-Drug Conjugates in Preclinical and Early Phase Clinical Trials